CompletedNCT02634320
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
This study evaluated the safety of Aripiprazole Lauroxil for people with schizophrenia.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
This study evaluated the safety of Aripiprazole Lauroxil for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 17 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 51
- Sponsor
- Alkermes, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02634320
- Official title
Show the full official title
Safety and Tolerability of Initiating Aripiprazole Lauroxil in Subjects With Schizophrenia Who Are Inadequately Treated With Paliperidone Palmitate or Risperidone Long Acting Injection
Recruitment & locations
CompletedLittle Rock · Rogers · Anaheim
14 more locations
- Culver City
- Garden Grove
- National City
- Oceanside
- Orange
- Panorama City
- Augusta
- Chicago
- Shreveport
- St Louis
- Garfield Heights
- Lincoln
- Dallas
- DeSoto
Questions about this study
What did researchers investigate?
This study evaluated the safety of Aripiprazole Lauroxil for people with schizophrenia.
Who is behind this study?
The study sponsor is Alkermes, Inc.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole Lauroxil.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia